Cargando…
Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609269/ https://www.ncbi.nlm.nih.gov/pubmed/28248313 http://dx.doi.org/10.1038/leu.2016.323 |
| _version_ | 1783604995200909312 |
|---|---|
| author | Harrison, C N Vannucchi, A M Kiladjian, J-J Al-Ali, H K Gisslinger, H Knoops, L Cervantes, F Jones, M M Sun, K McQuitty, M Stalbovskaya, V Gopalakrishna, P Barbui, T |
| author_facet | Harrison, C N Vannucchi, A M Kiladjian, J-J Al-Ali, H K Gisslinger, H Knoops, L Cervantes, F Jones, M M Sun, K McQuitty, M Stalbovskaya, V Gopalakrishna, P Barbui, T |
| author_sort | Harrison, C N |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7609269 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76092692020-11-05 Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis Harrison, C N Vannucchi, A M Kiladjian, J-J Al-Ali, H K Gisslinger, H Knoops, L Cervantes, F Jones, M M Sun, K McQuitty, M Stalbovskaya, V Gopalakrishna, P Barbui, T Leukemia Erratum Nature Publishing Group UK 2017-03-01 2017 /pmc/articles/PMC7609269/ /pubmed/28248313 http://dx.doi.org/10.1038/leu.2016.323 Text en © Macmillan Publishers Limited, part of Springer Nature. 2017 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Erratum Harrison, C N Vannucchi, A M Kiladjian, J-J Al-Ali, H K Gisslinger, H Knoops, L Cervantes, F Jones, M M Sun, K McQuitty, M Stalbovskaya, V Gopalakrishna, P Barbui, T Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis |
| title | Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis |
| title_full | Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis |
| title_fullStr | Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis |
| title_full_unstemmed | Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis |
| title_short | Erratum: Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis |
| title_sort | erratum: long-term findings from comfort-ii, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7609269/ https://www.ncbi.nlm.nih.gov/pubmed/28248313 http://dx.doi.org/10.1038/leu.2016.323 |
| work_keys_str_mv | AT harrisoncn erratumlongtermfindingsfromcomfortiiaphase3studyofruxolitinibvsbestavailabletherapyformyelofibrosis AT vannucchiam erratumlongtermfindingsfromcomfortiiaphase3studyofruxolitinibvsbestavailabletherapyformyelofibrosis AT kiladjianjj erratumlongtermfindingsfromcomfortiiaphase3studyofruxolitinibvsbestavailabletherapyformyelofibrosis AT alalihk erratumlongtermfindingsfromcomfortiiaphase3studyofruxolitinibvsbestavailabletherapyformyelofibrosis AT gisslingerh erratumlongtermfindingsfromcomfortiiaphase3studyofruxolitinibvsbestavailabletherapyformyelofibrosis AT knoopsl erratumlongtermfindingsfromcomfortiiaphase3studyofruxolitinibvsbestavailabletherapyformyelofibrosis AT cervantesf erratumlongtermfindingsfromcomfortiiaphase3studyofruxolitinibvsbestavailabletherapyformyelofibrosis AT jonesmm erratumlongtermfindingsfromcomfortiiaphase3studyofruxolitinibvsbestavailabletherapyformyelofibrosis AT sunk erratumlongtermfindingsfromcomfortiiaphase3studyofruxolitinibvsbestavailabletherapyformyelofibrosis AT mcquittym erratumlongtermfindingsfromcomfortiiaphase3studyofruxolitinibvsbestavailabletherapyformyelofibrosis AT stalbovskayav erratumlongtermfindingsfromcomfortiiaphase3studyofruxolitinibvsbestavailabletherapyformyelofibrosis AT gopalakrishnap erratumlongtermfindingsfromcomfortiiaphase3studyofruxolitinibvsbestavailabletherapyformyelofibrosis AT barbuit erratumlongtermfindingsfromcomfortiiaphase3studyofruxolitinibvsbestavailabletherapyformyelofibrosis |